Robert W. Baird Lowers LivaNova (NASDAQ:LIVN) Price Target to $55.00

LivaNova (NASDAQ:LIVN) had its target price lowered by analysts at Robert W. Baird from $57.00 to $55.00 in a note issued to investors on Thursday, Benzinga reports. The brokerage presently has a “neutral” rating on the stock. Robert W. Baird’s target price would indicate a potential upside of 11.34% from the stock’s previous close.

Several other equities research analysts have also recently weighed in on LIVN. StockNews.com upgraded shares of LivaNova from a “hold” rating to a “buy” rating in a research report on Thursday, April 25th. Mizuho lifted their price objective on shares of LivaNova from $75.00 to $80.00 and gave the stock a “buy” rating in a research note on Thursday, May 2nd. Needham & Company LLC lifted their price objective on shares of LivaNova from $72.00 to $75.00 and gave the stock a “buy” rating in a research note on Wednesday. Finally, Stifel Nicolaus lifted their price objective on shares of LivaNova from $70.00 to $72.00 and gave the stock a “buy” rating in a research note on Thursday, July 25th. Three analysts have rated the stock with a hold rating and four have given a buy rating to the company. Based on data from MarketBeat, LivaNova currently has a consensus rating of “Moderate Buy” and a consensus target price of $65.83.

LivaNova Trading Down 3.7 %

LivaNova stock opened at $49.40 on Thursday. The stock has a market cap of $2.68 billion, a P/E ratio of -82.33 and a beta of 0.99. The company has a debt-to-equity ratio of 0.50, a current ratio of 3.17 and a quick ratio of 2.71. LivaNova has a 1 year low of $42.75 and a 1 year high of $64.47. The firm’s 50 day moving average price is $54.49 and its 200-day moving average price is $54.44.

LivaNova (NASDAQ:LIVN) last announced its quarterly earnings results on Wednesday, May 1st. The company reported $0.73 earnings per share for the quarter, topping the consensus estimate of $0.45 by $0.28. LivaNova had a negative net margin of 2.68% and a positive return on equity of 13.59%. The company had revenue of $294.90 million for the quarter, compared to analysts’ expectations of $278.17 million. During the same quarter in the previous year, the business posted $0.43 earnings per share. LivaNova’s quarterly revenue was up 12.0% on a year-over-year basis. On average, equities analysts predict that LivaNova will post 2.6 earnings per share for the current fiscal year.

Insider Buying and Selling

In other LivaNova news, Director Daniel Jeffrey Moore sold 56,623 shares of the business’s stock in a transaction dated Monday, June 3rd. The shares were sold at an average price of $60.11, for a total value of $3,403,608.53. Following the completion of the transaction, the director now directly owns 27,534 shares in the company, valued at $1,655,068.74. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. 0.27% of the stock is owned by insiders.

Hedge Funds Weigh In On LivaNova

A number of large investors have recently added to or reduced their stakes in LIVN. Panagora Asset Management Inc. increased its holdings in shares of LivaNova by 29.4% during the second quarter. Panagora Asset Management Inc. now owns 236,176 shares of the company’s stock valued at $12,947,000 after acquiring an additional 53,718 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank increased its holdings in shares of LivaNova by 18.5% during the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 12,929 shares of the company’s stock valued at $709,000 after acquiring an additional 2,014 shares in the last quarter. Bank of New York Mellon Corp increased its holdings in shares of LivaNova by 4.2% during the second quarter. Bank of New York Mellon Corp now owns 506,105 shares of the company’s stock valued at $27,745,000 after acquiring an additional 20,275 shares in the last quarter. Fifth Third Bancorp increased its holdings in shares of LivaNova by 97.1% during the second quarter. Fifth Third Bancorp now owns 674 shares of the company’s stock valued at $37,000 after acquiring an additional 332 shares in the last quarter. Finally, Diversified Trust Co increased its holdings in shares of LivaNova by 7.9% during the second quarter. Diversified Trust Co now owns 13,902 shares of the company’s stock valued at $762,000 after acquiring an additional 1,012 shares in the last quarter. 97.64% of the stock is currently owned by institutional investors.

About LivaNova

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.